Form 4: Revolution Medicines CEO Sells Shares After Option Exercise

Revolution Medicines CEO Mark A. Goldsmith exercised stock options and subsequently sold a portion of his common stock holdings, including shares held in trusts, under a 10b5-1 plan.

Summary

• Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines, Inc. and a Director, reported transactions on November 25, 2025.
• Goldsmith acquired 60,000 shares of common stock by exercising stock options at a price of $4.09 per share.
• Concurrently, he disposed of 60,000 shares of common stock directly at a weighted average price of $75.0827 per share.
• An additional 3,000 shares were disposed of from the Jonathan Goldsmith Revocable Trust at $75.00 per share.
• Another 3,000 shares were disposed of from the Rebecca Goldsmith Revocable Trust at $75.00 per share.
• All reported transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.
• Following these transactions, Goldsmith directly beneficially owns 247,863 shares of common stock, which includes 193,475 restricted stock units.
• Indirect beneficial ownership includes 67,424 shares held by the Jonathan Goldsmith Revocable Trust, 67,424 shares held by the Rebecca Goldsmith Revocable Trust, and 570,050 shares held by the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Sentiment

Score: 5

Explanation: The filing reports a pre-planned insider transaction involving option exercise and subsequent sale of shares, which is a routine event for executives. The significant profit from the option exercise is positive for the individual, but the sale itself is neutral to slightly negative for market sentiment.

Positives

• The reporting person realized a significant profit from the exercise of stock options, acquiring shares at $4.09 and selling them at a weighted average price of $75.0827.

Negatives

• The sale of shares by a key executive, even if pre-planned, can sometimes be perceived negatively by the market.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Disposal of 3,000 shares from the Jonathan Goldsmith Revocable Trust at $75.00 per share.
• Disposal of 3,000 shares from the Rebecca Goldsmith Revocable Trust at $75.00 per share.

Stakeholder Impact

• Shareholders: Insider selling, even if pre-planned, can sometimes lead to short-term negative sentiment or questions about management's long-term conviction, although it is a common practice for executives to diversify holdings.

Key Dates

Recommendation

The filing details a pre-planned insider sale by the CEO following the exercise of stock options. While the sale itself represents a reduction in direct insider holdings, it was executed under a 10b5-1 plan, indicating it was not based on new, non-public information. The significant profit realized from the option exercise is notable. This type of transaction is common for executives and does not inherently signal a change in the company's fundamental outlook, thus a 'hold' recommendation is appropriate without further company-specific news.

Keywords

Revolution Medicines, RVMD, Mark A. Goldsmith, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, CEO, Director, Stock Sale